News - TherapySelect

Genomic Testing Cooperative lca (GTC) and TherapySelect have agreed to collaborate regarding the offer to the EU market of GTC's leading edge NGS diagnostic tests. Since May, 8th TherapySelect acts as authorized representative and importer for the European' Union for the following NGS diagnostics...

The SHIP-Event (short for „ Ship for Health Innovation Pitches“ ) is a competition for start-up s hosted by EIT Health Germany. It takes place during a cruise on the river Neckar. Aboard the „Königin Silvia“, 28 innovative companies went all out while presenting their projects. One of them was...

Dear Reader, within this newsletter we would like to inform you about the grants and awards, which TherapySelect and its cooperation partners received this year, as well as about further news. Grants of TherapySelect We are very pleased that we received a grant from the EIT Health Headstart...

Dear Reader, We are glad to inform you that we could publish research findings about our diagnostic CTR-Test® (Chemotherapy Resistance Test) within two publications this year: The first publication entitled “New in vitro system to predict chemotherapeutic efficacy of drug combinations in fresh...

Dear Reader, to further improve cancer patient care we are pleased to inform you that we are now able to offer exclusively an efficacy test based on the analysis of molecular-based biomarker for targeted drugs (including anti-hormone-drugs and immunotherapies) and chemotherapeutics. After careful...

Dear Reader, for the further improvement of patient care we are pleased to inform you that we are now able to offer a Liquid Biopsy for cancer therapy planning and monitoring as well as the possibility of tumor cell storage. Guardant360 ® The analysis of the Liquid Biopsy Guardant360 ® is performed...

Caris Molecular Intelligence ® Tumor Profiling from Caris Life Sciences for Optimzing Cancer Therapy is now Offered by TherapySelect in Germany Dear Reader, We are glad to inform you that we now offer an evaluation of effectiveness of targeted and selected chemotherapeutic drugs...

Personal Invitation to the Free Caris Symposium Concerning Therapy Optimization by CMI Diagnostics on 26.09.2015 in the Framework of the European Cancer Congress (ECCO) in Vienna Dear Reader, We are glad to invite you to the Caris Life Sciences CMI Symposium in the framework of...

Dear Reader, we are delighted to announce that since March 8th our new website has been online. The most important features are listed below: The website was completely redesigned. Now you can find information about our company and about our diagnostic services quickly and efficiently. Beside the...

<>For supporting the international business operation, it was necessary to provide multilingual information. Therefore the web page was revised and composed with appropriate new technologies. We hope this web page provides all important information in an easy and understandable way. In the...

CEIC is a German company which will distribute the CTR-Test ® and the Oncompass™ Service throughout the world. The cooperation is officially starting this month. Official website from CEIC

<>Smart Therapy Select is a Lebanese company distributing the CTR-Test ® exclusively in Lebanon. The cooperation is officially starting this month.

In April 2014 the Mayo Clinic, which is a worldwide leader in medical care, research and education, started to scan specific regions by Next-Generation Sequencing in 50 genes known to affect tumor growth for each cancer patients at their clinics. The other nonprofit Institute, Dana-Farber Cancer...

The DKFZ was founded in 1964. For the 50 years in business celebration, an anniversary issue was released containing a list of the 20 most cited publications which were published by the DKFZ within this period of time. These publications include two articles, which were written by Dr. Frank...

For further improvement of the CTR-Tests ® , the BMWi granted a funding for TherapySelect. In particular the number of drugs testable with the testing system will be increased within this project.

The BIOPRO releases an article about TherapySelect in the section "Biotechnologie & Pharma, Medizintehcnik, Diagnostick, Ernährung". The article is available online. Link to the online article "TherapySelect – identifying susceptibility to cancer therapy"...

<>As in the previous year, TherapySelect attends an important conference concerning personalized medicine for exchanging news about developments and progress in this field.

<>The principal investigator Prof. Sehouli (Charité Berlin) officially finished the recruitment of patients for the Predictor-Study. The aim, to recruit 100 female patients for the assessment of the diagnostic, is achieved. 123 tumor samples from primary disease were sent in. 9 samples were...

&lt;&gt;Due to significant additional expenses within the Predictor-Study, the funding of the project sponsor Jülich is officially extended for additional six months.

<>KPS and TherapySelect applied for a corporate development project which is authorized by the European Union. The project is named ONCOLINE (Oncological Decision Support System) and is an official EUREKA project. It aims to improve the personalized medication in oncology.

The Deutsche Welle publishes an online article about "coustom-fit cancer treatment". The article contains two interviews conderning this subject, one with Prof. Christof von Kalle (from NCT Heidelberg) and one with Dr. Frank Kischkel (TherapySelect). This...

Dr. Frank Kischkel was invited by BioRN to give a presentation about "Personalized Medicine" at the Biotechnica in Hannover. Presentation at the Biotechnica 2013

Dr. Frank Kischkel was invited by Emil-Schlegel-Klink to give a presentation on the "Day of Integrative Cancer Medicine" (06.07.). Interested patients as well as people from the medical field attended the event. Presentation on the "Day of Integrative Cancer Medicine"...

As in 2012 TherapySelect attends a important conference concerning personalized medicine for information exchange about new developments. TherapySelect uses the opportunity to present the CTR-Test ® . The focus was put on the utilization of the CTR-Test ® for pharmaceutical industry for improving...

<>After the Ethics Committee votes and the attendance of the centers are known, the recruitment of patients for the Predictor-Study will officially begin.

Dr. Frank Kischkel was invited by the Foundation Woman and Nature to give a presentaiton about personalized therapy in oncology at the first international conference for "Optimal Prevention and Threatment of Oncological Diseases". The conference took place at the 6th...

<>Dr. Frank Kischkel is in negotiation with KPS for a cooperation to offer the Oncompass™ Service in Germany. The official cooperation is initiated with the join presentation from KPS and Dr. Frank Kischkel at the conference of the European Society for Medical Oncology (ESMO) which takes...

<>Dr. Ferenc Pintér (CEO, KPS) and Dr. Frank Kischkel officially agree on cooperation. Thereby TherapySelect represents KPS and their services in Germany. KPS, Kft. Is a Hungarian cancer information provider. For the cooperation, KPS is going to launch a German office KPS Diagnostic GmbH,...

The PerMediCon is the most important conference for personalized medicine within Europe. Dr. Frank Kischkel was invited to present the CTR-Test ® especially for the pharmaceutical industry. Therefore Dr. Kischkel gave a presentation about the utilization of the CTR-Test ® for the improvement of...